Where Will Cyclacel Pharmaceuticals Inc (CYCC) Stock Go Next After It Is Down 14.18% in a Week?

The market has been down on Cyclacel Pharmaceuticals Inc (CYCC) stock recently. CYCC gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Cyclacel Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CYCC!

See Full CYCC Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CYCC Stock Today?

Cyclacel Pharmaceuticals Inc (CYCC) stock is down -11.19% while the S&P 500 is higher by 0.46% as of 2:57 PM on Wednesday, Mar 6. CYCC is down -$0.29 from the previous closing price of $2.59 on volume of 51,185 shares. Over the past year the S&P 500 has risen 26.02% while CYCC is down -79.52%. CYCC lost -$29.70 per share in the over the last 12 months. To screen for more stocks like Cyclacel Pharmaceuticals Inc click here.

More About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom. Click Here to get the full Stock Report for Cyclacel Pharmaceuticals Inc stock.